Better informing decision making with multiple outcomes cost-effectiveness analysis under uncertainty in ost-disutility space

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  McCaffrey, Nikki ^a   Agar, Meera ^a,b   Harlum, Janeane ^c   Karnon, Jonathon ^d   Currow, David ^a   Eckermann, Simon ^e  

^a FLINDERS UNIVERSITY   (Australia)

^b Braeside Hospital   (Australia)

^c SOUTH WESTERN SYDNEY LOCAL HEALTH DISTRICT   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; COST CONSEQUENCES ANALYSIS; COST DISUTILITY SPACE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; HEALTH CARE COST; HOME CARE; HUMAN; INTERMETHOD COMPARISON; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PATIENT CARE; QUANTITATIVE ANALYSIS; COST BENEFIT ANALYSIS; PROCEDURES; QUALITY ADJUSTED LIFE YEAR;

COST-BENEFIT ANALYSIS; DECISION MAKING; HEALTH CARE COSTS; HUMANS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84929485694     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115544     Document Type: Article

References (63)

1. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G (2005) Methods for the economic evaluation of health care programmes. Oxford, UK: Oxford University Press. p137-209 PMID: 15693028
2. Sindelar JL, Jofre-Bonet M, French MT, McLellan AT (2004) Cost-effectiveness analysis of addiction treatment: paradoxes of multiple outcomes. Drug and Alcohol Dependence 73: 41-50. PMID: 14687958
3. Al-Janabi H, McCaffrey N, Ratcliffe J (2013) Carer Preferences in Economic Evaluation and Healthcare Decision Making. The Patient-Patient-Centered Outcomes Research 6: 235-239.
4. Hoch JS, Dewa CS (2007) Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters. Pharmacoeconomics 25: 807-816. PMID: 17887803
5. Brooks R, Rabin R, de Charro F (2003) The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective. Dordrecht, The Netherlands: Kluwer Academic Publishers.
6. Ratcliffe J, Buxton M (1999) Patients' preferences regarding the process and outcomes of life-saving technology. An application of conjoint analysis to liver transplantation. Int J Technol Assess Health Care 15: 340-351. PMID: 10507193
7. Ratcliffe J, Van Haselen R, Buxton M, Hardy K, Colehan J, et al. (2002) Assessing patients' preferences for characteristics associated with homeopathic and conventional treatment of asthma: a conjoint analysis study. Thorax 57: 503-508. PMID: 12037224
8. Shih A, Schoenbaum S (2007) Measuring Hospital Performance: The Importance of Process Measures: The Commonwealth Fund.
9. Agar M, Currow DC, Shelby-James TM, Plummer J, Sanderson C, et al. (2008) Preference for place of care and place of death in palliative care: are these different questions? Palliative Medicine 22: 787-795. doi: 10.1177/0269216308092287 PMID: 18755830
10. McCaffrey N, Currow DC, Eckermann S (2009) Measuring Impacts of Value to Patients Is Crucial When Evaluating Palliative Care. Journal of Pain and Symptom Management 37: e7-e9. doi: 10.1016/ j.jpainsymman.2008.11.010 PMID: 19500720
11. Cohen S MB, Bruera E, Provost M, Rowe J, Tong K (1997) Validity of the McGill Quality of Life Questionnaire in the palliative care setting: a multicentre Canadian study demonstrating the importance of the existential domain. Palliative Medicine 11: 3-20. PMID: 9068681
12. Gold MR, Menzel P, Nord E, Pinto-Prades J-L, Richardson J, et al. (1999) Toward a Broader View of Values in Cost-Effectiveness Analysis of Health. The Hastings Center Report. p7.
13. Currow DC, Burns C, Agar M, Phillips J, McCaffrey N, et al. (2011) Palliative Caregivers Who Would Not Take on the Caring Role Again. Journal of Pain and Symptom Management 41: 661-672. doi: 10. 1016/j.jpainsymman.2010.06.017 PMID: 21227632
14. Al-Janabi H, Flynn TN, Coast J (2011) QALYs and carers. PharmacoEconomics 29: 1015-1023. doi: 10.2165/11593940-000000000-00000 PMID: 22077576
15. Brazier JE, Rowen D, Mavranezouli I, Tsuchiya A, Young T, et al. (2012) Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome). Health Technol Assess 16: 1-114.
16. Eckermann S, Karnon J, Willan AR (2010) The Value of Value of Information: Best Informing Research Design and Prioritization Using Current Methods. PharmacoEconomics 28: 699-709. doi: 10.2165/ 11537370-000000000-00000 PMID: 20629473
17. Sculpher MJ, Price M (2003) Measuring costs and consequences in economic evaluation in asthma. Respir Med 97: 508-520. PMID: 12735668
18. Coast J (2004) Is economic evaluation in touch with society's health values? BMJ 329: 1233-1236. PMID: 15550430
19. Briggs A, O'Brien B (2001) The Death of Cost-Minimization Analysis? Health Economics 10: 179-184. PMID: 11252048
20. Briggs AH, O'Brien BJ, Blackhouse G (2002) Thinking Outside the Box: Recent Advances in the Analysis and Presentation of Uncertainty in Cost-Effectiveness Studies. Annual Reviews Public Health 23: 377-401.
21. Eckermann S, Willan AR (2007) Expected value of information and decision making in HTA. Health Economics 16: 195-209. PMID: 16981193
22. Eckermann S, Pekarsky B (2014) Can the real opportunity cost stand up: displaced services, the straw man outside the room. Pharmacoeconomics 32: 319-325. doi: 10.1007/s40273-014-0140-3 PMID: 24515251
23. Claxton K (2008) Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics 26: 781-798. PMID: 18767898
24. Eckermann S, Briggs A, Willan A (2008) Health technology assessment in the cost-disutility plane. Medical Decision Making 28: 172-181. doi: 10.1177/0272989X07312474 PMID: 18356312
25. Eckermann S, Willan A (2011) Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies. PharmacoEconomics 29: 563-577. doi: 10.2165/ 11587100-000000000-00000 PMID: 21671686
26. Eckermann S, Coelli T (2013) Including quality attributes in efficiency measures consistent with net benefit: creating incentives for evidence based medicine in practice. Soc Sci Med 76: 159-168. doi: 10.1016/j.socscimed.2012.10.020 PMID: 23153543
27. McCaffrey N, Agar M, Harlum J, Karnon J, Currow D, et al. (2013) Is home-based palliative care costeffective? An economic evaluation of the Palliative Care Extended Packages at Home (PEACH) pilot. BMJ Supportive & Palliative Care 3: 431-435.
28. Stinnett AA, Mullahy J (1998) Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Medical Decision Making 18: S68-80. PMID: 9566468
29. Willan AR, Lin DY (2001) Incremental net benefit in randomized clinical trials. Stat Med 20: 1563-1574. PMID: 11391688
30. Zethraeus N, Johannesson M, Jonsson B, Lothgren M, Tambour M (2003) Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies. Pharmacoeconomics 21: 39-48. PMID: 12484802
31. Stinnett A (1996) Net Health Benefits: a new framework for the evaluation of uncertainty in medical cost-effectiveness analysis. Medical Decision Making 16: 463.
32. Birch S, Gafni A (1992) Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be? J Health Econ 11: 279-296. PMID: 10122540
33. Pekarsky B (2010) Should financial incentives be used to differentially reward 'me-too' and innovative drugs? PharmacoEconomics 28: 1-17. doi: 10.2165/11587410-000000000-00000 PMID: 21182340
34. Pekarsky B (2012) Trusts, constraints and the counterfactual: reframing the political economy of new drugs (PhD dissertation). University of Adelaide.
35. Fenwick E, Byford S (2005) A guide to cost-effectiveness acceptability curves. Br J Psychiatry 187: 106-108. PMID: 16055820
36. Eckermann S (2004) Hospital Performance Including Quality: Creating Economic Incentives Consistent with Evidence-Based Medicine. (PhD Dissertation), University of New South Wales, Sydney.
37. Farrell MJ (1957) The Measurement of Productive Efficiency. Journal of the Royal Statistical Society Series A (General) 120: 253-290.
38. McCaffrey N, Karnon J, Currow D, Eckermann S (2010) The Old Dog & the Poor Relation: Informing funding decisions in palliative care with cost-consequence analysis in the cost-disutility plane. Palliative Medicine 24: S207. doi: 10.1177/0269216310366390 PMID: 20522880
39. Coelli T (1996) A guide to DEAP Version 2.1: A data envelopment analysis (computer) program. CEPA Working Papers. Armidale, NSW 2351: Department of Econometrics, University of New England.
40. Campbell MK, Torgerson DJ (1999) Bootstrapping: estimating confidence intervals for costeffectiveness ratios. QJM 92: 177-182. PMID: 10326078
41. Arrow KJ, Lind RC (1970) Uncertainty and the Evaluation of Public Investment Decisions. The American Economic Review 60: 364-378.
42. Hanson LC, Winzelberg G (2013) Research priorities for geriatric palliative care: goals, values, and preferences. J Palliat Med 16: 1175-1179. doi: 10.1089/jpm.2013.9475 PMID: 24007351
43. Pharmaceutical Benefits Advisory Committee (2008) Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3). Canberra: Department of Health & Ageing, Commonwealth of Australia.
44. National Institute for Clinical Excellence (2008) Guide to the methods of technology appraisal. London, UK: National Institute for Clinical Excellence.
45. McCaffrey N, Currow DC (2010) Psychometric development of a single-item end-of-life patient-reported outcome (EOLPRO): the first piece of the puzzle. Palliative Medicine, 24: s58.
46. Williams I, McIver S, Moore D, Bryan S (2008) The use of economic evaluations in NHS decisionmaking: a review and empirical investigation. Health Technology Assessment 12: 1-58. PMID: 18796263
47. Bjorner J, Keiding H (2004) Cost-effectiveness with multiple outcomes. Health Economics 13: 1181-1190. PMID: 15386670
48. Negrin MA, Vazquez-Polo FJ (2006) Bayesian cost-effectiveness analysis with two measures of effectiveness: the cost-effectiveness acceptability plane. Health Econ 15: 363-372. PMID: 16259048
49. Lemmens KM, Nieboer AP, Rutten-Van Molken MP, van Schayck CP, Asin JD, et al. (2010) Application of a theoretical model to evaluate COPD disease management. BMC Health Serv Res 10: 81. doi: 10. 1186/1472-6963-10-81 PMID: 20346135
50. Hawe P, Ghali L (2008) Use of social network analysis to map the social relationships of staff and teachers at school. Health Educ Res 23: 62-69. PMID: 17289659
51. Hawe P, Shiell A (2000) Social capital and health promotion: a review. Soc Sci Med 51: 871-885. PMID: 10972431
52. Hawe P, Shiell A, Riley T (2004) Complex interventions: how "out of control" can a randomised controlled trial be? BMJ 328: 1561-1563. PMID: 15217878
53. Hawe P, Shiell A, Riley T (2009) Theorising interventions as events in systems. Am J Community Psychol 43: 267-276. doi: 10.1007/s10464-009-9229-9 PMID: 19390961
54. Shiell A, Hawe P (1996) Health promotion community development and the tyranny of individualism. Health Econ 5: 241-247. PMID: 8817298
55. Shiell A, Hawe P, Gold L (2008) Complex interventions or complex systems? Implications for health economic evaluation. BMJ 336: 1281-1283. doi: 10.1136/bmj.39569.510521.AD PMID: 18535071
56. Eckermann S, Dawber J, Yeatman H, Quinsey K, Morris D (2014) Evaluating return on investment in a school based health promotion and prevention program: The investment multiplier for the Stephanie Alexander Kitchen Garden National Program. Soc Sci Med 114: 103-112. doi: 10.1016/j.socscimed. 2014.05.056 PMID: 24922607
57. Tsiachristas A, Cramm JM, Nieboer A, Rutten-van Molken M (2013) Broader economic evaluation of disease management programs using multi-criteria decision analysis. Int J Technol Assess Health Care 29: 301-308. doi: 10.1017/S0266462313000202 PMID: 23759317
58. Postmus D, Tervonen T, van Valkenhoef G, Hillege HL, Buskens E (2013) A multi-criteria decision analysis perspective on the health economic evaluation of medical interventions. Eur J Health Econ. Jul 11 (epub ahead of print).
59. McCaffrey N (2013) Modelling joint cost and multiple outcomes uncertainty on the cost-disutility plane: case studies in palliative care (PhD dissertation). Central Library: Flinders University.
60. Willan AR, Eckermann S (2012) Value of information and pricing new healthcare interventions. Pharmacoeconomics 30: 447-459. doi: 10.2165/11592250-000000000-00000 PMID: 22591129
61. Kent S, Briggs A, Eckermann S, Berry C (2013) Are value of information methods ready for prime time? An application to alternative treatment strategies for NSTEMI patients. Int J Technol Assess Health Care 29: 435-442. doi: 10.1017/S0266462313000433 PMID: 24290337
62. Claxton K, Briggs A, Buxton MJ, Culyer AJ, McCabe C, et al. (2008) Value based pricing for NHS drugs: an opportunity not to be missed? Bmj 336: 251-254. doi: 10.1136/bmj.39434.500185.25 PMID: 18244997
63. Koerkamp BG, Hunink MGM, Stijnen T, Hammitt JK, Kuntz KM, et al. (2007) Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Medical Decision Making 27: 101(111). PMID: 17409361